phrykt

Aura Biosciences, Inc. (AURA): who owns it and who trades it

As of Nov 16, 2026, AURA insiders reported 12 open-market sales worth $40M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Matrix Capital Management Company, LP (10% owner), with $39M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Aura Biosciences

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns AURA

146 funds and institutions reported AURA shares worth $699M at the end of Q2 2026, about 95% of the company. The largest holder is TCG Crossover Management, LLC with 9.2%.

Funds and institutions (13F) 95%Everyone else 5%

10 largest owners, by share of the company

TCG Crossover Management, LLC9.2%
Montanova Capital, LLC6.9%
Frazier Life Sciences Management, L.P.6.8%
Nantahala Capital Management, LLC5.7%
Long Focus Capital Management, LLC4.9%
BlackRock, Inc.4.5%
Adage Capital Partners Gp, L.l.c.4.5%
Caligan Partners LP4.1%
Vanguard Capital Management LLC3.9%
Fcpm III Services B.v.3.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
TCG Crossover Management, LLC9.53M9.16%$67.7M–
Montanova Capital, LLC7.21M6.92%$51.2M+65%
Frazier Life Sciences Management, L.P.7.10M6.82%$50.4M+39%
Nantahala Capital Management, LLC5.90M5.67%$41.9M+179%
Long Focus Capital Management, LLC5.12M4.92%$36.3M+11%
BlackRock, Inc.4.71M4.52%$33.4M+31%
Adage Capital Partners Gp, L.l.c.4.64M4.46%$32.9M-5%
Caligan Partners LP4.30M4.13%$30.5M+1770%
Vanguard Capital Management LLC4.10M3.94%$29.1M+83%
Fcpm III Services B.v.4.05M3.90%$28.8M–
Orbimed Advisors LLC3.33M3.20%$23.7M–
Medicxi Ventures Management (Jersey) Ltd3.04M2.92%$21.6MNo change
Jupiter Topco LLC2.50M2.40%$17.8M–
Ra Capital Management, L.P.2.50M2.40%$17.8M–
Balyasny Asset Management L.P.2.35M2.26%$16.7M+322%
Franklin Resources Inc2.07M1.99%$14.7MNo change
Geode Capital Management, LLC1.75M1.69%$12.5M+34%
Redmile Group, LLC1.67M1.60%$11.8M–
EcoR1 Capital, LLC1.67M1.60%$11.8M–
Trails Edge Capital Partners, LP1.44M1.39%$10.2M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, AURA insiders reported $0 of open-market purchases and $40M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$40M
12 trades, 7 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 16, 2026
Filed Nov 16, 2026

Purchases and sales by month

$39M$39MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 16, 2026Janet Jill HopkinsChief Medical OfficerSale16,903$7.05$119KForm 4
Jun 16, 2026Anthony S GibneySee RemarksSale12,824$6.42$82.3KForm 4
May 7, 2026Matrix Capital Management Company, LP +110% ownerSale6.92M$5.64$39MForm 4
Apr 16, 2026Conor KilroySee RemarksSale11,738$7.02$82.4KForm 4
Feb 17, 2026Conor KilroySee RemarksSale12,079$5.05$61KForm 4
Feb 17, 2026Mark PlavsicChief Technology OfficerSale15,890$5.05$80.2KForm 4
Feb 17, 2026Janet Jill HopkinsChief Medical OfficerSale20,401$5.06$103KForm 4
Feb 17, 2026Amy ElazzouziVice presidentSale8,549$5.06$43.3KForm 4
Feb 17, 2026los Pinos Elisabet deDirectorSale47,648$5.06$241KForm 4
Jan 20, 2026Amy ElazzouziVice presidentSale1,581$4.86$7.7KForm 4
Jan 20, 2026los Pinos Elisabet deDirectorSale16,928$4.86$82.3KForm 4
Nov 17, 2025Janet Jill HopkinsChief Medical OfficerSale17,109$5.42$92.7KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Matrix Capital Management Company, LP10% owner–$39MMay 7, 2026
los Pinos Elisabet deSee Remarks, Director–$323KFeb 17, 2026
Janet Jill HopkinsChief Medical Officer–$315KNov 16, 2026
Conor KilroySee Remarks–$143KApr 16, 2026
Anthony S GibneySee Remarks–$82.3KJun 16, 2026
Mark PlavsicChief Technology Officer–$80.2KFeb 17, 2026
Amy ElazzouziSenior Vice President, Finance–$50.9KFeb 17, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

AURA short interest

High short interest. 10.1% of AURA shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 232%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 10.46M AURA shares were sold short, 10.1% of the shares outstanding, down 3.9% from the report before. At the average daily volume of 765,417 shares, buying them all back would take about 13.7 trading days (days to cover).

Shares short, % of all shares

10.1%May 15Oct 3011.7%

Days to cover

13.7May 15Oct 3020.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202610.46M10.09%-4%765,41713.7
Oct 15, 202610.89M10.50%+5%1.02M10.6
Sep 30, 202610.37M10.00%+47%1.12M9.2
Sep 15, 20267.05M6.80%+14%604,73011.7
Aug 31, 20266.20M5.98%+1%972,2306.4
Aug 14, 20266.16M5.94%-3%622,0799.9
Jul 31, 20266.36M9.91%+13%344,39418.5
Jul 15, 20265.61M8.74%-19%692,7448.1
Jun 30, 20266.93M10.81%+29%742,1979.3
Jun 15, 20265.39M8.40%+43%521,87710.3
May 29, 20263.76M5.87%+19%496,4367.6
May 15, 20263.16M4.92%+44%1.13M2.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Aura Biosciences company events

Aura Biosciences filed 10 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026AnnouncementThe Company updated its corporate presentation for use in meetings with investors, analysts, and others. Filing
  2. Aug 11, 2026LeadershipThe Board appointed Susan Abu-Absi, Ph.D., age 52, as the Company’s Chief Operating Officer, effective as of August 10, 2026. Filing
  3. Aug 5, 2026VoteReported shareholder vote results. Filing
  4. Jul 8, 2026LeadershipThe Board of Directors of Aura Biosciences, Inc. increased the size of the Board from six to seven directors and unanimously appointed Jeremy Bender, Ph.D., M.B.A., as a Class II director, effective July 7, 2026, to fill the newly created vacancy. Filing
  5. Jun 11, 2026VoteReported shareholder vote results. Filing
  6. May 11, 2026AnnouncementThe Company updated its corporate presentation for use in meetings with investors, analysts, and others. Filing
  7. May 5, 2026AgreementAura Biosciences, Inc. entered into an underwriting agreement with Leerink Partners LLC, TD Securities (USA) LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein, relating to an underwritten public offering (including the offering of the Option Shares (as… Filing
  8. May 4, 2026AgreementAura Biosciences, Inc. and Matrix Capital Management Master Fund, LP entered into a stock purchase agreement pursuant to which the Company has agreed to repurchase, in a privately negotiated transaction, up to 6,922,870 shares of its common stock, which the Company believes represents all shares of… Filing
  9. May 4, 2026LeadershipThe Board of Directors of Aura Biosciences, Inc. appointed Natalie Holles as the Company’s Chief Executive Officer and President and as a Class I director with a term expiring at the Company’s 2028 annual meeting of stockholders, effective as of April 30, 2026. Filing
  10. Mar 30, 2026AnnouncementThe Company updated its corporate presentation for use in meetings with investors, analysts, and others. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Aura Biosciences financials

Famous investors that hold AURA

4 of the 50 well-known investors we track reported holding AURA in their latest 13F filing. The largest position is Ken Griffin's, worth $1.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026304,523$1.9M0.0%+487%
Steve Cohen · Point72 Asset ManagementQ3 2026164,651$1M0.0%+822%
Jim Simons · Renaissance TechnologiesQ3 2026140,084$880K0.0%-20%
Ken Fisher · Fisher Asset ManagementQ3 202683,508$524K0.0%No change

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 10 filings named AURA in the last 120 days.

FiledHolderFormStake
Nov 16, 2026ADAR1 Capital Management, LLC13G5.2%
Nov 16, 2026ADAR1 Capital Management, LLC13G5.2%
Nov 16, 2026TCG Crossover GP II, LLC13G/A5.0%
Nov 16, 2026TCG Crossover GP II, LLC13G/A5.0%
Nov 13, 2026Montanova Capital, LLC13G/A2.9%
Nov 13, 2026Montanova Capital, LLC13G/A2.9%
Oct 27, 2026BlackRock, Inc.13G5.0%
Oct 27, 2026BlackRock, Inc.13G5.0%
Oct 1, 2026ForGrowth III PA B.V.13G5.1%
Oct 1, 2026ForGrowth III PA B.V.13G5.1%

Questions about Aura Biosciences, Inc. (AURA) stock

Who owns the most AURA stock?

The largest reported owner of Aura Biosciences, Inc. (AURA) is TCG Crossover Management, LLC, with 9.2% of the company. In total, 146 funds and institutions reported holding AURA at the end of Q2 2026, together about 95% of the shares. See the largest owners.

Are AURA insiders buying or selling?

In the last 12 months, AURA insiders reported no open-market purchases and 12 sales worth $40M. The latest trade was on Nov 16, 2026. See every trade.

What is the short interest in AURA?

As of Oct 30, 2026, 10.46M AURA shares were sold short, 10.1% of the shares outstanding, down 3.9% from the report before. At the average daily volume of 765,417 shares, buying them all back would take about 13.7 trading days (days to cover). See the history.

Which famous investors hold AURA?

4 of the 50 well-known investors we track reported AURA in their latest 13F filing, including Ken Griffin, Steve Cohen, Jim Simons. The largest position is worth $1.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.